These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22778808)

  • 1. ACS chemical neuroscience molecule spotlight on Lorcaserin.
    Hopkins CR
    ACS Chem Neurosci; 2010 Nov; 1(11):718-9. PubMed ID: 22778808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lorcaserin: an investigational serotonin 2C agonist for weight loss.
    Hurren KM; Berlie HD
    Am J Health Syst Pharm; 2011 Nov; 68(21):2029-37. PubMed ID: 22011982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Directly Observable Behavioral Effects of Lorcaserin in Rats.
    Serafine KM; Rice KC; France CP
    J Pharmacol Exp Ther; 2015 Dec; 355(3):381-5. PubMed ID: 26384326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and development of 5-HT(₂C) receptor agonists for obesity: is there light at the end of the tunnel?
    Miller KJ; Wacker DA
    Future Med Chem; 2010 Dec; 2(12):1761-75. PubMed ID: 21428799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of impulsivity and reward in the anti-obesity actions of 5-HT
    Higgins GA; Zeeb FD; Fletcher PJ
    J Psychopharmacol; 2017 Nov; 31(11):1403-1418. PubMed ID: 29072522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.
    Nigro SC; Luon D; Baker WL
    Curr Med Res Opin; 2013 Jul; 29(7):839-48. PubMed ID: 23574263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists.
    Higgins GA; Sellers EM; Fletcher PJ
    Trends Pharmacol Sci; 2013 Oct; 34(10):560-70. PubMed ID: 24041919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.
    Thomsen WJ; Grottick AJ; Menzaghi F; Reyes-Saldana H; Espitia S; Yuskin D; Whelan K; Martin M; Morgan M; Chen W; Al-Shamma H; Smith B; Chalmers D; Behan D
    J Pharmacol Exp Ther; 2008 May; 325(2):577-87. PubMed ID: 18252809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential.
    Higgins GA; Fletcher PJ; Shanahan WR
    Pharmacol Ther; 2020 Jan; 205():107417. PubMed ID: 31629010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of lorcaserin in the management of obesity.
    Hess R; Cross LB
    Postgrad Med; 2013 Nov; 125(6):62-72. PubMed ID: 24200762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats.
    Levin ED; Johnson JE; Slade S; Wells C; Cauley M; Petro A; Rose JE
    J Pharmacol Exp Ther; 2011 Sep; 338(3):890-6. PubMed ID: 21636655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability review of lorcaserin in clinical trials.
    Greenway FL; Shanahan W; Fain R; Ma T; Rubino D
    Clin Obes; 2016 Oct; 6(5):285-95. PubMed ID: 27627785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis.
    Nguyen CT; Zhou S; Shanahan W; Fain R
    Clin Ther; 2016 Jun; 38(6):1498-1509. PubMed ID: 27206567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of chemically diverse 5-HT₂c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles.
    Higgins GA; Silenieks LB; Lau W; de Lannoy IA; Lee DK; Izhakova J; Coen K; Le AD; Fletcher PJ
    Psychopharmacology (Berl); 2013 Apr; 226(3):475-90. PubMed ID: 23184281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Potential of 5-HT2C Receptor Agonists for Addictive Disorders.
    Higgins GA; Fletcher PJ
    ACS Chem Neurosci; 2015 Jul; 6(7):1071-88. PubMed ID: 25870913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 5-HT₂C receptor agonist, lorcaserin, and the 5-HT₆ receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour.
    Higgs S; Cooper AJ; Barnes NM
    Psychopharmacology (Berl); 2016 Feb; 233(3):417-24. PubMed ID: 26507195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Serotonin 2C Receptor Agonist Lorcaserin Attenuates Intracranial Self-Stimulation and Blocks the Reward-Enhancing Effects of Nicotine.
    Zeeb FD; Higgins GA; Fletcher PJ
    ACS Chem Neurosci; 2015 Jul; 6(7):1231-40. PubMed ID: 25781911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of lorcaserin in obesity: a systematic review and meta-analysis of randomized controlled trials.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2020 Feb; 13(2):183-190. PubMed ID: 31815555
    [No Abstract]   [Full Text] [Related]  

  • 19. A Positive Allosteric Modulator of the Serotonin 5-HT
    García-Cárceles J; Decara JM; Vázquez-Villa H; Rodríguez R; Codesido E; Cruces J; Brea J; Loza MI; Alén F; Botta J; McCormick PJ; Ballesteros JA; Benhamú B; Rodríguez de Fonseca F; López-Rodríguez ML
    J Med Chem; 2017 Dec; 60(23):9575-9584. PubMed ID: 29116785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-HT(2C) receptor agonists and the control of appetite.
    Halford JC; Harrold JA
    Handb Exp Pharmacol; 2012; (209):349-56. PubMed ID: 22249823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.